DJIA 17,630.27 189.68 1.09%
NASDAQ 5,089.21 49.43 0.98%
S&P 500 2,093.25 25.61 1.24%
market minute promo

Seattle Genetics (NASDAQ: SGEN)

48.93 0.87 (1.81%)

REAL-TIME: Last trade at

Extended Hours: $49.00 $0.07 (0.14%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

SGEN $48.93 1.81%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $48.39
Previous Close $48.06
Daily Range $47.83 - $49.18
52-Week Range $30.05 - $52.33
Market Cap $6.1B
P/E Ratio -72.82
Dividend (Yield) $0.00 (0.0%)
Volume 630,319
Average Daily Volume 869,738
Current FY EPS -$0.80

Sector

Healthcare

Industry

Drug Makers

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

News & Commentary Rss Feed

Is This Why the Street Keeps Doubting Gilead Sciences, Inc.?

Gilead Sciences looks like a screaming buy right now based on its fundamentals. But the Street apparently doesn't think so. Here's why.

First Week of SGEN March 2016 Options Trading

How To Make Money In Small To Nano-Cap Biotech

Interesting SGEN Put And Call Options For August 21st

Seattle Genetics' Collaborative Approach To Fighting Cancer Makes It A Buy

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the Intern

Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutic

The Zacks Analyst Blog Highlights: Regeneron, Vertex, Celgene, Seattle Genetics and SAGE Therapeutics - Press Releases

Seattle Genetics-Unum Therapeutics Tie Up for Cancer Drugs - Analyst Blog

3 Stocks Improving Performance Of The Drugs Industry

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant

Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Seattle Genetics Larger Than S&P 500 Component Tenet Healthcare

See More SGEN News...

SGEN's Top Competitors

SGEN $48.93 (1.81%)
Current stock: SGEN
AMGN $172.74 (4.35%)
Current stock: AMGN
GILD $113.07 (2.29%)
Current stock: GILD
BIIB $319.93 (3.39%)
Current stock: BIIB